Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
The present invention relates to novel compounds and formulations thereof which compounds are ligands, e.g., agonists or antagonists, for a metabotropic glutamate receptor or a NAALADase enzyme or both. The present invention also relates to methods of modulating the activity of a metabotropic glutamate receptor or a NAALADase enzyme or both, e.g., in a subject in need thereof, using a compound or formulation of the present invention. The present invention also relates to methods of treating a subject suffering from a chronic or acute disease, malady or condition due at least in part to an abnormality in the activity of an endogenous metabotropic glutamate receptor or a NAALADase enzyme or both, using a compound or formulation of the present invention.
1. A method of inhibiting NAALADase in a mammal, comprising the step of administering to a mammal an inhibitory effective amount of a compound of the formula:
wherein
Bn is benzyl;
R 2 is selected from the group consisting of hydrogen, alkyl, and amino;
and wherein the stereochemical configuration at any stereocenter of the compound is R or S or a mixture thereof.
2. A method of agonizing a metabotropic glutamate receptor in a mammal, comprising the step of administering to a mammal an agonizing effective amount of a compound of the formula:
wherein
Bn is benzyl;
R 2 is selected from the group consisting of hydrogen, alkyl, and amino;
and wherein the stereochemical configuration at any stereocenter of the compound is R or S or a mixture thereof.
3. A method of antagonizing a metabotropic glutamate receptor in a mammal, comprising the step of administering to a mammal an antagonizing effective amount of a compound of the formula:
wherein
Bn is benzyl;
R 2 is selected from the group consisting of hydrogen, alkyl, and amino;
and wherein the stereochemical configuration at any stereocenter of the compound is R or S or a mixture thereof.
4. A method of agonizing a single subtype of metabotropic glutamate receptor in a mammal, comprising the step of administering to a mammal an agonizing effective amount of a compound of the formula:
wherein
Bn is benzyl;
R 2 is selected from the group consisting of hydrogen, alkyl, and amino;
and wherein the stereochemical configuration at any stereocenter of the compound is R or S or a mixture thereof.
5. A method of antagonizing a single subtype of metabotropic glutamate receptor in a mammal, comprising the step of administering to a mammal an antagonizing effective amount of a compound of the formula:
wherein
Bn is benzyl;
R 2 is selected from the group consisting of hydrogen, alkyl, and amino;
and wherein the stereochemical configuration at any stereocenter of the compound is R or S or a mixture thereof.
6. A method of treating a neurological disorder wherein the neurological disorder is ischaemia, which method comprises the step of administering to a mammal an antagonizing effective amount of a compound of formula 1:
wherein
X is selected from the group consisting of —C(O)—, —C(S)—, —S(O) 2 —, —C(R)(OR)—, and —C(R)(SR)—;
Y is selected, independently for each occurrence, from the group consisting of (CR 2 ) n , (NR) n , and a bond;
Z is selected, independently for each occurrence, from the group consisting of C(R), C(NR 2 ), and C(NHacyl);
W is selected, independently for each occurrence, from the group consisting of (CR 2 ) m , (NR) m , and a bond;
G is selected, independently for each occurrence, from the group consisting of H, —COOH, —SO 3 H, —P(O)(OH) 2 , —SR, and 2-R-tetrazol-5-yl;
R is selected, independently for each occurrence, from the group consisting of H, alkyl, heteroalkyl, aryl, heteroaryl, and aralkyl; and also including a negative charge for instances of R bonded to a heteroatom;
m and n are integers selected, independently for each occurrence, from the range 0 to 3 inclusive; wherein the antagonizing effective amount of the compound of formula I inhibits formation and accumulation of glutamate.
7. A method of treating a neurological disorder wherein the neurological disorder is ischaemia, which method comprises the step of administering to a mammal an antagonizing effective amount of a compound of the formula 2:
wherein
X is selected from the group consisting of —C(O)—, —C(S)—, —P(O)(OR)—, —S(O) 2 —, —C(R)(OR)—, and —C(R)(SR)—;
Y is selected, independently for each occurrence, from the group consisting of (CR 2 ) n , (NR) n , and a bond;
G is selected, independently for each occurrence, from the group consisting of H, —COOH, —SO 3 H, —P(O)(OH) 2 , and 2-R-tetrazol-5-yl;
R is selected, independently for each occurrence, from the group consisting of H, alkyl, heteroalkyl, aryl, heteroaryl, and aralkyl; and also including a negative charge for instances of R bonded to a heteroatom;
n is an integer selected, independently for each occurrence, from the range 0 to 3 inclusive; wherein the antagonizing effective amount of the compound of formula 2 inhibits formation and accumulation of glutamate.
8. A method of treating a neurological disorder wherein the neurological disorder is ischaemia, which method comprises the step of administering to a mammal an antagonizing effective amount of a compound of the formula:
wherein
Bn is benzyl;
R 2 is selected from the group consisting of hydrogen, alkyl, and amino;
and wherein the stereochemical configuration at any stereocenter of the compound is R or S or a mixture thereof; wherein the antagonizing effective amount of the compound of said formula inhibits formation and accumulation of glutamate.
9. A method of treating a neurological disorder wherein the neurological disorder is ischaemia, which method comprises the step of administering to a mammal an antagonizing effective amount of a compound of formula:
wherein the antagonizing effective amount of the compound inhibits formation and accumulation of glutamate.